Discover a groundbreaking webinar delving into the use of artificial intelligence (AI) and machine learning (ML) in preclinical drug research and related regulatory frameworks. The challenges and opportunities of integrating AI into preclinical drug research and development workflows are of increasing importance, especially in the context of regulatory science expectations. On the one hand, legislative priorities seek to reduce the cost of healthcare and drugs, while also reducing the burden of testing on animals through the use of technology like AI.
Discover a groundbreaking webinar delving into the use of artificial intelligence (AI) and machine learning (ML) in preclinical drug research and related regulatory frameworks. The challenges and opportunities of integrating AI into preclinical drug research and development workflows are of increasing importance, especially in the context of regulatory science expectations.
In this recording, leaders from the FDA and VeriSIM Life share their perspectives on where and how AI is being applied within the preclinical phase of the drug development lifecycle, how scientific regulators are working with stakeholders today to responsibly leverage AI, and what needs to be done to continue evolving the state of AI for the benefit of all patients.